Development of Nanocarriers for Cancer-Targeted Drug Delivery

Systemic administration of therapeutic agents (TA) and biologics (proteins/ siRNA) for the treatment of cancer and neurodegenerative diseases is a common practice. However, their presence in normal tissues leads to adverse toxicities, limiting the administered dose and the resulting treatment efficacy. This undue toxicity can potentially be avoided if the TA remains inactive until exposed to the intended organ, within a well-defined volume. We are developing biodegradable formulations of our preclinical and clinically active drugs and biologics to improve their safety and minimize toxicity.  Our experimental compounds and pre-approved drugs will be encapsulated into nanoparticles such as liposomes, polymeric micelles, and lipid-polymer hybrids, for both targeted and non-targeted delivery of therapeutics. We use state-of-the-art equipment and techniques to design and characterize our nano-formulations, and validate them using cell and animal models.

Disease models:

Triple Negative Breast Cancer, Prostate Cancer and Glioblastoma

Infographic of Development of Nanocarriers for Cancer-Targeted Drug Delivery

Participating Collaborative Universities/ Institutes: